ArticleJournal of extracellular biology2026
Flow Cytometric Detection of Biomarker Changes in CFDA-SE-Labelled Plasma Extracellular Vesicles Using a Rodent Pregnancy Model of Prenatal Diagnostics.
Article in Journal of extracellular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating extracellular vesicles (EVs) offer a promising source of non-invasive biomarkers for congenital disease diagnostics but robust assays for their detection are lacking. We used a rodent pregnancy model as a proxy for a prenatal diagnostics assay to test whether we could detect a difference in EV tetraspanin display between pregnant rats and non-pregnant controls using standard flow cytometry. Carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) was used as a positive EV marker. CFDA-SE positive particle count was linear but both size and concentration were below those measured by nanoparticle tracking analysis. Plasma proteins activated CFDA-SE non-specifically. Fractional analysis of eluates revealed that plasma protein is efficiently separated from EVs by size-exclusion chromatography (SEC). We identify albumin within antibody storage buffers as the main source of false positives. Attempts to reduce background by quenching (trypan blue) and clean-up (SEC) methods were ineffective. We then probed CFDA-SE-labelled EVs with antibodies to assay surface biomarker display using a quadrant method to measure double-positive EVs. We observed a reduction in CD63 display in the pregnant condition but no change in CD9 or CD81. Using CD63 display level as a diagnostic test allowed detection of the pregnant condition with a sensitivity of 0.83 at specificity of 1 (AUC = 0.99).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.